Literature DB >> 12640679

Differential effects between amphoterin and advanced glycation end products on colon cancer cells.

Hiroki Kuniyasu1, Yoshitomo Chihara, Hideaki Kondo.   

Abstract

Amphoterin is 1 ligand of the receptor for advanced glycation end products (RAGE). We studied expression of amphoterin and RAGE mRNA and proteins in colorectal carcinoma cells and investigated their associations with the invasive activities of cells exposed to advanced glycation end products (AGE). Expression of RAGE and amphoterin was examined in 4 colorectal carcinoma cell lines. All cell lines expressed both RAGE and amphoterin. The effects of RAGE and amphoterin on cell growth (MTT assay), migration (wound healing assay) and invasion (in vitro invasion assay) were tested by treatment of cells with RAGE and amphoterin antisense S-oligodeoxynucleotides (ODNs). Cell growth, migration and invasion were inhibited significantly in Colo320 and WiDr carcinoma cells treated with RAGE and amphoterin antisense S-ODNs compared with sense-treated cells. Differences in ligand activity between amphoterin and AGE were examined with AGE-bovine serum albumin (BSA). AGE-BSA decreased cell growth, migration and invasion of amphoterin antisense S-ODN-treated Colo320 and WiDr cells compared with those of cells treated with Colo320 conditioned medium. Phosphorylation of extracellular signal-regulated kinase-1/2, Rac1 and AKT and production of matrix metalloproteinase 9 were increased to a greater degree by amphoterin than by AGE-BSA. In contrast, production of inducible nitric oxide synthase and nuclear factor-kappaBp65 were increased to a greater degree by AGE-BSA than by amphoterin. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12640679     DOI: 10.1002/ijc.11016

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  42 in total

1.  Downregulation of the nucleosome-binding protein 1 (NSBP1) gene can inhibit the in vitro and in vivo proliferation of prostate cancer cells.

Authors:  Ning Jiang; Li-Qun Zhou; Xiao-Yu Zhang
Journal:  Asian J Androl       Date:  2010-06-07       Impact factor: 3.285

Review 2.  HMG chromosomal proteins in development and disease.

Authors:  Robert Hock; Takashi Furusawa; Tetsuya Ueda; Michael Bustin
Journal:  Trends Cell Biol       Date:  2006-12-13       Impact factor: 20.808

3.  Plasma high-mobility group box 1 as an indicator of surgical stress.

Authors:  Atsushi Osoegawa; Tokujiro Yano; Takeharu Yamanaka; Tetsuzo Tagawa; Fumihiro Shoji; Ichiro Yoshino; Akinobu Taketomi; Hiroyuki Ito; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  Surg Today       Date:  2011-07-12       Impact factor: 2.549

4.  Advanced glycation end products (AGEs) activate mast cells.

Authors:  E Sick; S Brehin; P André; G Coupin; Y Landry; K Takeda; J P Gies
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

5.  Correlation of HMGB1 expression to progression and poor prognosis of adenocarcinoma and squamous cell/adenosquamous carcinoma of gallbladder.

Authors:  Zilu Shi; Qian Huang; Jian Chen; Pengcheng Yu; Xiaosong Wang; Hong Qiu; Yijie Chen; Yangyang Dong
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

6.  Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas.

Authors:  Tomonori Sasahira; Yoshihiko Akama; Kiyomu Fujii; Hiroki Kuniyasu
Journal:  Virchows Arch       Date:  2005-03-24       Impact factor: 4.064

7.  Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products.

Authors:  Jun-Ichi Takino; Sho-Ichi Yamagishi; Masayoshi Takeuchi
Journal:  J Oncol       Date:  2010-06-29       Impact factor: 4.375

8.  Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer.

Authors:  Chu-Biao Zhao; Ji-Ming Bao; Yong-Jie Lu; Tong Zhao; Xin-Hua Zhou; Da-Yong Zheng; Shan-Chao Zhao
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

9.  The expression of HMGB1 protein and its receptor RAGE in human malignant tumors.

Authors:  Nora Kostova; Stanislava Zlateva; Iva Ugrinova; Evdokia Pasheva
Journal:  Mol Cell Biochem       Date:  2009-10-30       Impact factor: 3.396

10.  Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma.

Authors:  Xingjun Yao; Gang Zhao; Hongfa Yang; Xinyu Hong; Li Bie; Guojin Liu
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-07       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.